William Blair & Company
IRD

William Blair & Company’s Opus Genetics IRD Stock Holding History

William Blair & Company’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.7K Sell
12,466
-15,000
-55% -$51.9K ﹤0.01% 1682
2025
Q4 		$55.2K Buy
27,466
+3,000
+12% +$6.09K ﹤0.01% 1646
2025
Q3 		$40.4K Hold
24,466
– – ﹤0.01% 1665
2025
Q2 		$23K Hold
24,466
– – ﹤0.01% 1669
2025
Q1 		$24K Sell
24,466
-8,801
-26% -$9.83K ﹤0.01% 1651
2024
Q4 		$39.6K Hold
33,267
– – ﹤0.01% 1632
2024
Q3 		$43.6K Hold
33,267
– – ﹤0.01% 1648
2024
Q2 		$50.9K Hold
33,267
– – ﹤0.01% 1597
2024
Q1 		$66.9K Hold
33,267
– – ﹤0.01% 1566
2023
Q4 		$100K Hold
33,267
– – ﹤0.01% 1505
2023
Q3 		$111K Hold
33,267
– – ﹤0.01% 1490
2023
Q2 		$144K Buy
+33,267
New +$158K ﹤0.01% 1463

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

William Blair & Company's IRD Position: Q1 2026 in Review

William Blair & Company reduced its Opus Genetics (IRD) stake by 55% in Q1 2026, selling an estimated $51.9K and leaving 12,466 shares worth $56.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1682.

William Blair & Company first reported a position in IRD in Q2 2023 and has held it in 12 quarters since. The position peaked at $144K in Q2 2023. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • William Blair & Company held 12,466 shares of Opus Genetics worth $56.7K as of Q1 2026.
  • William Blair & Company sold 15,000 Opus Genetics shares in Q1 2026, an estimated $51.9K.
  • Opus Genetics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1682 holding.
  • William Blair & Company first reported a position in Opus Genetics in Q2 2023 and has held it in 12 quarters since.
  • William Blair & Company's Opus Genetics position peaked at $144K in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.